NCT07487194

Brief Summary

The primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving pancreas transplants using donor pancreata transported via the PancreasPak system. These results will be compared to standard of care outcomes, as well as other preservation methods.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
66mo left

Started Jun 2026

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress4%
Jun 2026Jan 2032

First Submitted

Initial submission to the registry

March 17, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 23, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

June 1, 2026

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2031

Expected
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2032

Last Updated

March 23, 2026

Status Verified

March 1, 2026

Enrollment Period

5 years

First QC Date

March 17, 2026

Last Update Submit

March 17, 2026

Conditions

Outcome Measures

Primary Outcomes (8)

  • Graft dysfunction

    The percentage of subjects in each cohort who experience graft dysfunction post-transplant.

    Post-transplant through 1 year post-transplant

  • Pancreatitis

    The percentage of subjects in each cohort who experience pancreatitis post-transplant.

    Post-transplant through 1 year post-transplant

  • Primary Non-Function

    The percentage of subjects in each cohort who primary non-function post transplantation.

    Post-transplant through 7 days post-transplant

  • Length of Hospital Stay

    How many days the patients stays in the hospital post-transplant.

    1 year

  • Surgical Complications

    The percentage of subjects in each cohort who experience surgical complications.

    Post-transplant through 1 year post-transplant

  • Insulin Dependence

    The percentage of subjects in each cohort who experience insulin dependence post-transplant.

    Post-transplant through 1 year post-transplant

  • Graft Failure

    The percentage of subjects in each cohort who develop graft failure post-transplant.

    Post-transplant through 1 year post

  • Survival

    The percentage of subjects in each cohort who survive through 1 year post-transplant.

    Post-transplant through 1 year post

Secondary Outcomes (4)

  • Length of ICU Stay

    1 year

  • Interventions for Anastomotic Complications

    Post-transplant through 1 year post-transplant

  • Intervention for Vascular Complications

    Post-transplant through 1 year-post transplant

  • Medications

    Post-transplant through 1 year post-transplant

Study Arms (2)

PancreasPak patient

Patients whose donor pancreas was transported with the PancreasPak device.

Device: PancreasPak

Standard method patients

Patients whose donor pancreas was transported with a method other than the PancreasPak device.

Interventions

The PancreasPak Donor Preservation System is a FDA cleared and CE-marked medical device intended to be used for the static hypothermic preservation of donor pancreata during transportation and eventual transplantation using cold preservation solutions indicated for use in donor pancreata transplantation. The intended organ preservation time for the PancreasPak system is up to 21 hours.

PancreasPak patient

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who have received a pancreas transplant at centers that use the PancreasPak device.

You may qualify if:

  • Adult or pediatric recipients of pancreas alone, simultaneous pancreas-kidney, or pancreas after kidney transplant

You may not qualify if:

  • Donor pancreata that do not meet institutional clinical requirements for transplantation
  • Simultaneous pancreas-kidney transplant recipients who received donor organs from multiple donors

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pancreatic Diseases

Condition Hierarchy (Ancestors)

Digestive System Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 17, 2026

First Posted

March 23, 2026

Study Start

June 1, 2026

Primary Completion (Estimated)

June 1, 2031

Study Completion (Estimated)

January 1, 2032

Last Updated

March 23, 2026

Record last verified: 2026-03